Artiva Biotherapeutics nets $120m Series B
Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company, has secured $120 million in Series B financing.
Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company, has secured $120 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination